Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

New Bribery Allegations Hit Glaxosmithkline Plc In China-Reuters


Sunday, 7 Jul 2013 11:37pm EDT 

Reuters reported that Glaxosmithkline Plc allegedly handed doctors with cash and other rewards for prescribing Botox, according to the Wall Street Journal, in the latest scandal to hit the British drugmaker which is under investigation by Chinese police for economic crimes. Internal documents and email showed GSK's China sales staff were also apparently instructed to use their personal email addresses to discuss marketing strategies related to Botox, the report added. Citing an internal email dated May 13, a whistleblower notified GSK's board of directors and compliance officers of the allegations that its China sales staff bribed doctors to prescribe Botox over the past year, the paper reported on Sunday. The same anonymous whistleblower earlier made allegations that GSK sales representatives in China were involved in widespread bribery to get doctors to prescribe the Company's medicines, the report added. GSK officials could not be immediately reached for comment when contacted by Reuters. The Wall Street Journal quoted a company spokesman as saying: 'We believe they come from the same source who has made previous claims of alleged corruption and bribery in our China business.' 

Company Quote

43.21
1.17 +2.78%
18 Dec 2014